Fes Inhibitors
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Herbimycin A | 70563-58-5 | sc-3516 sc-3516A | 100 µg 1 mg | $272.00 $1502.00 | 13 | |
Herbimycin A is a notable compound characterized by its ability to disrupt protein-protein interactions through specific binding to target kinases. Its unique structural features enable it to modulate signaling pathways, particularly those involved in cell growth and differentiation. The compound exhibits distinct reaction kinetics, influencing the phosphorylation state of various substrates. Additionally, its hydrophobic regions enhance membrane permeability, facilitating cellular uptake and interaction with intracellular targets. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
A tyrosine kinase inhibitor that can interfere with BCR-ABL kinase, which is linked to the same signaling pathways as Fes, potentially inhibiting its activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Another tyrosine kinase inhibitor, known to affect Src family kinases, which are connected to Fes signaling, thereby possibly reducing Fes activity. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $74.00 $119.00 | 33 | |
Targets the epidermal growth factor receptor (EGFR), a protein interacting with Fes signaling pathways, potentially diminishing Fes activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Inhibits multiple tyrosine kinases, including VEGFR and PDGFR, which are part of pathways overlapping with Fes, possibly leading to reduced Fes signaling. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
A multi-targeted tyrosine kinase inhibitor, affects pathways shared with Fes, potentially reducing its signaling capacity. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
Inhibits VEGFR, PDGFR, and c-Kit, which are involved in pathways parallel to Fes, potentially leading to diminished Fes activity. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Primarily targets BCR-ABL, similar to Imatinib, and can indirectly influence Fes signaling through shared pathways. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Targets EGFR, thus affecting pathways that intersect with those regulated by Fes, potentially reducing its activity. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Inhibits both EGFR and HER2/neu, affecting signaling pathways that are interconnected with Fes, potentially leading to reduced Fes activity. | ||||||